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Bioregulatory systems medicine (BrSM) is a paradigm that aims to advance current
medical practices. The basic scientific and clinical tenets of this approach embrace an
interconnected picture of human health, supported largely by recent advances in systems
biology and genomics, and focus on the implications of multi-scale interconnectivity
for improving therapeutic approaches to disease. This article introduces the formal
incorporation of these scientific and clinical elements into a cohesive theoretical model
of the BrSM approach. The authors review this integrated body of knowledge and
discuss how the emergent conceptual model offers the medical field a new avenue for
extending the armamentarium of current treatment and healthcare, with the ultimate goal
of improving population health.
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Introduction
For over a decade, discoveries in systems biology have catalyzed new waves of thinking in
medicine. Systems and network theory, coupled with advances in technologies analyzing vast
datasets, are propagating novel perspectives of human health, disease, and patient treatment.
In this paper, we define a systems approach as a method for describing the human body as
a complex biological network of interconnected components (molecules, cells, tissues, organs).
Since the turn of the century, scientific communities around the globe have been driven by the
revolutionary insights garnered from the Human Genome Project. Many recently established
initiatives aim to translate these insights in a way that is practically relevant to medical treatment
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(P4 Medicine Institute, 2012; Cesario et al., 2014; CASYM1). A
key area of ongoing research relates to expanding empirically-
based clinical knowledge that supports the applicability of
systems medicine concepts. A unidirectional, discovery-oriented
approach undoubtedly results in innovative diagnostic and
therapeutic solutions. We suggest that a more bidirectional
approach that connects the dots between scientific discoveries
and clinical application may also reveal some important medical
innovations that are highly relevant to a broad range of healthcare
practitioners.
In this paper, we introduce a medical paradigm that further
develops insight from systems biology by merging its key
scientific principles with relevant empirical evidence into a
treatment model. We call this approach “bioregulatory systems
medicine” (BrSM). BrSM is rooted in the idea that a more robust
and effective solution for disease complexity should optimize an
individual’s homeostatic systems and their interactions across
all levels of biological organization. From the detailed picture
of protein homeostasis at the molecular level, for example, to
temperature and blood pressure regulation at the broader, whole-
organism level, the interconnected web of these systems and their
impact on individual health status constitutes a cardinal focus of
this therapeutic approach.
Like other paradigms grounded in systems biology, BrSM
emerges in part as a response to the limitations of the reductionist
perspective that is central in the current healthcare model
(Tillmann et al., 2015). The reductionist perspective tends to
view the human organism as a compilation of targets for
individual intervention and symptom alleviation. Clinicians
typically specialize in particular fields focused on single systems
or tissues of the body, and concentrate largely on symptom
expression in evaluating and treating disease (Stange, 2009).
Since the widespread adoption of the current healthcare
model in the 1960s, medical costs have escalated as much as
15 times (Gaygisiz, 2010), and rates of chronic disease are
projected to increase more than 50% by 2023 (Bodenheimer
et al., 2009). Nonetheless, medical care is currently estimated
to account for only 10% of health outcomes, while as much
as 80% are influenced by environmental and lifestyle factors
(McGinnis et al., 2002). It behooves the field to consider
how medical care can effectively address the impact of these
environmental and lifestyle factors that have such profound
influences on health (Miller and Jones, 2014). We propose that
the medical and financial burdens associated with the current
healthcare model can ultimately be tied to neglecting a basic
tenet of systems biology in clinical care: relatively simple network
perturbations can have large and unintended consequences.
Indeed, the prevailing linear mode of intervention can be linked
to increasing rates of iatrogenesis, unnecessary diagnostics, and
multiple practitioner consultations, which collectively contribute
to escalating healthcare costs and inefficiencies in patient
treatment (Ahn et al., 2006; James, 2013). These inefficiencies, in
turn, contribute to the growth in disease incidence that burdens
1CASYM. Europe - Coordinating Action Systems Medicine. Implementation of
Systems Medicine across Europe. Available online at: www.casym.eu
society today, which is arguably more complex than what can be
explained and resolved by the reductionist approach.
The significant contributions of the dominant healthcare
approach cannot be diminished. Emergency and acute care,
vaccines, surgery, and preventative medicine are among the
major healthcare advances of the past century. Nonetheless,
the specialized context within which many clinicians treat
patients today, combined with limited incorporation of biological
complexity as part of treatment, has curtailed the capacity
to resolve many chronic and lifestyle-related diseases that
manifest at the systems level. The complexity of the human
organism cannot be reduced to a parts list of molecules,
which yields little functional understanding of regulatory
networks (Oltvai and Barabási, 2002). Instead, genomics and
computational network modeling must be used to better
understand and treat diseases from a more integrated, higher-
order perspective.
At the heart of BrSM is an appreciation of the patient
autoregulatory capacity in light of lessons from systems biology.
Whereas human biology exists as nested levels of physiological
networks, i.e., molecular, cellular, tissue, organ, system, etc.,
the autoregulatory capacity includes both the specific networks
within this hierarchy as well as the interactions between them.
BrSM embraces this interconnectivity among networks as the
global autoregulatory network, and posits that the state of an
individual’s autoregulatory network is a key determinant and
indicator of patient health. The patient autoregulatory network
is also a key therapeutic access point in BrSM (Figure 1).
Until now, the concept of BrSM has existed as a loose set
of scientific, clinical, and empirical evidence that support the
general idea of autoregulation and its role in health and disease.
Against the backdrop of systems biology, we aim to begin
answering the questions: What are the details of these concepts
that are pertinent to a cohesive approach that can improve
clinical outcomes? How are these details interrelated, and what is
the significance of this interrelatedness for advancing therapeutic
practice? Consequently, a team of scientists and clinicians set
out to systematically bring together those elements most critical
to BrSM, and to engage in an initiative to conceptualize an
integrated, cohesive model of this approach. An emphasis on
multiple disciplines not only ensured that cutting-edge research
from various fields was included in formalizing the paradigm,
but also that the model was more likely to resonate with and
demonstrate applicability to a broad community of scientists and
clinicians.
The purpose of this paper is to present the BrSM model
that resulted from this initiative. This model lays important
groundwork for scientists and clinicians to begin the research and
data collection necessary to fully realize the potential advantages
of this approach. For a medical community that has been
educated, practicing, and thinking within a largely reductionist
framework for some time, the shift toward incorporating a
systems biology view of the human organism can be challenging.
We envision BrSM and the underlying principles in this model as
a strategic guide for connecting and applying emerging research
in a way that will lead clinicians toward realizing improvement in
patient outcomes.
Frontiers in Physiology | www.frontiersin.org 2 August 2015 | Volume 6 | Article 225
Goldman et al. Bioregulatory systems medicine
FIGURE 1 | New perspective on factors affecting disease. Current
medical paradigms (A) typically consider etiological factors, genetic
predisposition, and molecular pathways recruited in pathogenesis as key
causative agents that lead to disease. Bioregulatory systems medicine also
considers the compromised or insufficient patient autoregulatory capacity to
restore homeostasis (B) as a key factor that influences individual disease
incidence and manifestation. Relatedly, bioregulatory systems medicine
includes the interactions among multi-scale homeostatic systems that
comprise the global autoregulatory network as the primary therapeutic
access point in treating signs, symptoms, and underlying causes of individual
disease. While lifestyle changes, removal of triggers, and inhibition of
pathogenetic pathways are also potential solutions, bioregulatory systems
medicine emphasizes the restoration of individual autoregulation capacity as
the potent therapeutic approach.
Materials and Methods
Fundamental to this initiative was first selecting the appropriate
range of participant expertise and professional experience to
contribute to the model development, and then engaging these
viewpoints in a group conceptualization process that would
systematically integrate the key elements into a cohesive model.
The following steps were taken to achieve these goals:
1. Initiative leaders identified and approached participants
that collectively possessed considerable breadth and depth
of relevant expertise. Scientific experts included those in
the fields of immunology, genomics, molecular biology,
neuroscience, and systems biology. Clinicians specializing in
various medical areas were also involved, including family
and community medicine, chronic diseases, aging, cardiology,
pediatrics, and neurology.
2. Group concept mapping was selected as the most appropriate
method for the model development process given its prior
use in similar projects (Baldwin et al., 2004; Kane and
Trochim, 2007; Kagan et al., 2009). The method is capable
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of systematically integrating particularly complex ideas,
perspectives, and their relational properties, such as those used
to create this model. The group-authored visual outputs are
based entirely on the combination of individual participant
perspectives, and provide fertile ground for generating group
consensus on the interpretation and meaning of the results.
3. Participants generatedmodel content (statements) in response
to a single guiding sentence completion: “A specific idea
or element that is fundamental to defining and explaining
a model of BrSM is. . . ” Content was generated through an
iterative process of abstraction from focused literature review
and discussion and refinement with expert participants.
4. Participants individually sorted the resultant 102 statements
into piles based on their own understanding of their
relatedness and using a dedicated project website. Readers are
referred to Kane and Trochim (2007) for a detailed description
of the sorting process.
5. Analysis of participant sorting arrangements included
aggregation of individual binary sort matrices (a “1” was
placed in a cell if a participant sorted the statements in
the corresponding row and column into the same pile; a
“0” was placed in a cell if the participant did not sort the
corresponding statements together). The 29 participant sort
matrices were then summed, creating a total similarity matrix.
The total similarity matrix was then subjected to multi-
dimensional scaling, producing a two-dimensional visual
representation (point map) of the 102 statements. Proximity
among statements indicates their relative similarity, such that
the closer two statements appear on the point map, the more
similar or related they are thought to be by the group as a
whole, and vice versa.
6. Hierarchical clustering was applied to the point map to
group statements in shared territories of the map into non-
overlapping clusters based on the Euclidian distances between
them. The smaller set of resulting clusters allows participants
to consider the model through the lens of higher-order themes
that capture the specific details of the underlying content.
A 10 cluster solution was determined by initiative leaders
to be the most parsimonious and meaningfully interpretable
representation of the model content.
7. Finally, initiative leaders and participants reviewed the cluster
map as part of a multi-day meeting, and labeled each cluster in
a way that articulated the commonality among its constitutive
statements, and in a way that conveyed the constructs’
relevance in the context of the model as a whole (Figure 2)
(Supplementary Table 1).
Results: Interpretation of the Bioregulatory
Systems Medicine Model
From the group concept mapping process, a two-dimensional
point map was generated to visualize the emergent group
consensus. The cluster map represents the 102 statements
as they are grouped into 10 higher-order themes based
on their arrangement in the point map (Figure 2). Cluster
analysis revealed four anchor themes (Inflammation Physiology,
Biological Communication at the Microenvironment-Scale,
Biological Communication across Multi-Scale Networks,
Bioregulatory Clinical Pharmacology) and six intermediary
themes (Inflammatory Network Response to Perturbation,
Microenvironment Response to Inflammation, Diagnostics
and Therapeutic Strategy, Clinical Focus on Dysregulation,
Autoregulation of Biological Networks, Patient Health-Disease
Continuum). From these conceptual patterns, two axes emerged.
The horizontal Biological Information axis suggests how
clinicians evaluate characteristics of the disease, serving as a
guide for clinical decision-making, while the vertical Resolution
Processes axis considers mechanisms of intervention.
As we move to our interpretation, detailing the conceptual
basis of the model axes and clusters, we remind readers that
the unique scope and content of each cluster exists as an
emergent product of the expert participants’ perspectives. The
cluster arrangements that underpin this interpretation could
each plausibly constitute their own paper, as each include their
own unique set of scientifically grounded statements that could
be explored in depth. Because this paper is an introduction
to the BrSM concept, we center our discussion on reviewing
participants’ perceptions of the content interrelatedness, and the
emergent themes that capture how the key components of the
paradigm formulate an organized conceptualization of treatment.
The collective spatial properties of the model also convey
emergent properties that reflect participants’ integrated
understanding of the approach’s medical and clinical
components. At the broadest level, we can examine conceptual
patterns that reveal how the content is distributed across the two-
dimensional model representation, and consider the meaning
of this distribution in terms of its practical and theoretical
implications.
The content closest to the Biological Communication at
the Microenvironment-Scale cluster relates most strongly to
communication and signaling at the cellular level, particularly
as it occurs within and by way of the extracellular matrix.
The content located closest to the Biological Communication
across Multi-Scale Networks cluster resonates with a systems-
level understanding of how information flows betweenmolecular
networks/organ systems at the whole organism level. Collectively,
this conceptual through-line contains elements related to the
role of biological information at both relatively “micro” and
“macro” levels. We label this dimension (or axis) as Biological
Information, across which informational content is present at
varying levels of specificity depending on its position along the
dimension and in relation to other information-related elements
of the model.
Perpendicular to Biological Information, experts
distinguished among relatively internal and external resolution
mechanisms. Closest to the Inflammation Physiology cluster,
the model content relates strongly to the human organism’s
natural ability to reach resolution in the face of perturbation,
particularly as it relates to inflammation process mechanisms.
At the opposite end of this dimension, the Bioregulatory Clinical
Pharmacology cluster describes the use and application of
therapeutics in the clinical context in order to reach resolution.
As all content along this axis relates in some manner to
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FIGURE 2 | The bioregulatory systems medicine model. This figure
depicts the 10 constructs that emerged from the concept mapping process,
reflecting expert consensus on the key elements of the bioregulatory systems
medicine approach. Underlying the constructs (clusters) are the 102
statements that comprise the basic scientific and clinical elements of the
approach. The labels assigned to each cluster reflect the shared theme of its
specific statements and in relation to the contents of every other cluster
(Supplementary Table 1). From a more empirical perspective, the 10 model
clusters can also be considered within four thematic groupings. The
autoregulation clusters (Biological Communication across Multi-Scale
Networks, Biological Communication at the Microenvironment-Scale, and
Inflammation Physiology) describe the physiological autoregulation of
biological networks. The dysregulation clusters (Inflammatory Network
Response to Perturbation and Microenvironment Response to Inflammation)
describe the biological networks’ response to perturbation. The central
position of Patient Health-Disease Continuum conveys its influence on both
the autoregulation and dysregulation clusters. This concept can be
interpreted as a correlation between dysregulation and autoregulation,
representing the resultant disease state of a patient along the health-disease
continuum. The adjacent cluster, Autoregulation of Biological Networks,
reinforces the concept of autoregulation as the common, systems
biology-based denominator underlying the model. The remaining clusters are
therapy-related. Diagnostics and Therapeutic Strategy links a patient’s
autoregulatory status with clinical decision-making. Clinical Focus on
Dysregulation describes local aspects of dysregulation, suggesting that
certain molecular networks can be targeted using bioregulatory therapeutics
depending on the nature of their dysregulation. Bioregulatory Clinical
Pharmacology connects clinical decision-making and intervention tactics.
participants’ conceptualization of resolution, we label this axis of
the map as Resolution Processes.We recognize that in some cases
resolution pertains to the organism’s innate capacity to reach
resolution, and in other cases to the use of external interventions
as part of treatment.
Even more specifically, those clusters most centrally aligned
on either end of each dimension serve as conceptual anchors
that ground the BrSM model in its key clinical focuses.
The Inflammation Physiology and Bioregulatory Clinical
Pharmacology clusters convey the “how” of physiological
coherence and restoration, leading clinicians to explore
questions about intervention such as: How do the inflammatory
processes function to influence autoregulation, and what are
the physiological factors involved? How should bioregulating
medications be designed and applied to effectively restore
autoregulation?
Likewise, the Biological Communication at the
Microenvironment-Scale and Biological Communication
across Multi-Scale Networks clusters specify those elements
necessary to understand the range of biological signaling and
communication pathways that underlie autoregulation. This
content prompts the clinician to explore questions of: What
is taking place at the cellular or “micro” level of the human
organism that influences regulatory capability? What is taking
place at the network, or “macro” level to influence regulation
across systems? At the “micro” level, emphasis is placed on
the role of the extracellular matrix in pathological conditions,
particularly with regard to the accumulation of toxins, disease
progression, and transcription patterns. At the “macro”
level, information and signaling across molecular networks
direct regulatory action among organ systems, such that the
large-scale complexity of the cellular-level interactions can be
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understood as an integrated, interconnected picture of human
health.
The emergence of these clusters as conceptual anchors is
also validated methodologically. Structurally (spatially), these
four clusters are more densely populated with statements than
the other clusters of the map, indicating that participants
perceived a higher degree of conceptual similarity among the
set of items in each of these four clusters relative to the other
clusters. The density of these clusters implies a high degree of
consensus from experts, suggesting that participants collectively
understood a greater degree of clarity and distinctiveness in the
meaning of these sets of items relative to the other clusters.
Functionally, these clusters demonstrate the highest degree of
internal relatedness, indicating that participants understood the
statements in each of these four clusters as more strongly related
to one another and less related to the statements in the other
clusters of the model. These clusters are also the functional
anchors of the map in the sense that they function as the
cohesive, agreed-upon, foundational classes of information from
which the conceptual role of the other six clusters can be
considered.
Experts considered the other six clusters as conceptual bridges
that articulate relationships among the anchors that they reside
between. Structurally, these clusters occupy a comparatively
larger area of the map and are overall less densely populated
with statements than the anchors. Their relatively expansive
area suggests that participants perceived considerable similarity
among the set of items in these clusters and the set of items in
their respective adjacent anchors. Their value in the approach is
optimally derived from their ability to build coherence among the
anchor constructs, and logically bridge the core elements in a way
that can be practically applied in the clinical context. Thus, we
refer to these six clusters as the intermediary clusters.
Microenvironment Response to Inflammation, for example,
brings together the physiology of inflammation with “micro” or
local level information regulation to describe the environment
in which inflammation initiation and resolution take place.
Inflammatory Network Response to Perturbation articulates
the mechanisms of inflammation with a more thorough
understanding of the systemic and informational components of
this physiological process. Diagnostics and Therapeutic Strategy
conveys the practical use of “macro” or global network level
information in the design and application of medication
with bioregulatory properties. This cluster emphasizes the
use of diagnostics, such that autoregulatory networks can be
appropriately assessed and, in turn, interpreted in a way that
will effectively guide treatment. The content in this area also
highlights the use of diagnostics for furthering our knowledge
of disease evolution and thereby enhancing strategic therapeutic
decision-making. Clinical Focus on Dysregulation identifies
specific conditions and pathologies for which BrSM is well suited,
although additional content, particularly regarding toxicity,
may be helpful in fully realizing the relationship between the
extracellular matrix and the clinical context.
Patient Health-Disease Continuum occupies a unique position
in the center of the map, where one can envision the intersection
of the Resolution Processes and Biological Information axes. This
cluster emerges as the “hub” that personalizes the theoretical
foundation of the model, emphasizing the individual, patient-
centric basis of BrSM. As the structural core, this construct
includes clinician considerations for optimizing resolution, as
well as critical biological information for the clinician to
consider in improving patient condition. Symptoms, disease
progression, autoregulatory abilities, and inflammation are
informative expressions of an individual’s health status that can
be used to personalize treatment.
These thematic patterns reveal principles of the BrSM model
that are rooted in experts’ understanding of the elements’
interrelatedness, beyond the statement and cluster content
alone. To summarize the model results at the theoretical level,
the bioregulatory systems approach is driven by the goal of
stimulating resolution processes through the communication
and information pathways of the human organism. The
model conveys that a clinically integrated picture of biological
information, when utilized to restore coherence following
perturbation, constitute the two fundamental concepts for
approaching patient disease using BrSM.
We now move to explore in greater depth the key principles
of BrSM that connect the model results with a clinically relevant
understanding of this approach.
Key Principles of the BrSM Approach
A Network Structure of Health and Disease: The
Influence of Molecular Network Information Flow
on Autoregulatory Capacity
It comes with little surprise that participants recognized the
complexity intrinsic to biological systems as a core feature
of the BrSM model. Given that systems biology serves as a
primary scientific backdrop that fuels this approach, a holistic
understanding of the human body as a multi-scale, multi-level
regulatory network percolates the entire concept map (Hunter
et al., 2002; PacificBiosciences, 2011; Castiglione et al., 2014)
(Figure 3). The complexity of a systems approach challenges
common reductionist thinking, and paves the way for medicine
that workswith rather than against the inherent interconnectivity
of biological organization.
Participants conceptualized health and disease in the context
of this interconnectivity. A healthy system is one that self-
regulates in the face of network perturbation (Buchman,
2002). We refer to this self-regulation as autoregulation. Model
participants embraced autoregulatory capacity as a defining
mechanism of human health. The concept of robustness is used
in tandem with autoregulation to characterize the functional
characteristics of a healthy system. Whereas biological networks
are inherently dynamic and unstable, a robust system is one
that is able to adapt to and cope with this instability as
it is received from the environment (Kitano, 2004, 2007a,b;
Kitano et al., 2004). Some readers may liken the concept of
robustness to homeostasis; however, participants distinguished
that in the context of BrSM, homeostasis is a property that
maintains the state of a system, whereas robustness assumes
a more dynamic, active network state, and refers to sustained
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FIGURE 3 | Multi-scale autoregulatory networks in the BrSM
model. Bioregulatory systems medicine encompasses a systems
biology perspective of interactions within and across multiple levels of
biological organization. From the molecular to cellular to organ to
whole organism network, the BrSM model acknowledges that human
health and disease are driven by the regulatory information flow that
propagates throughout this global autoregulatory network. Current
diagnostic approaches are limited by capturing only a static snapshot
of some of this information recorded as medical records. Novel
diagnostic approaches will not only confirm and provide higher
resolution of existing snapshots of clinical information, but will also
expand the scope of medical records by adding (surrogate) biomarkers
of autoregulation that will correlate all captured information in one
spatiotemporal model specific to the patient.
system functionality, even in the face of stresses or perturbations.
Individual autoregulatory abilities support network robustness.
Metabolic, gene and protein networks interconnect to create a
global biochemical network, while the feedback loops across these
networks constitute the foundation of the global autoregulatory
network of the human organism (Droujinine and Perrimon,
2013).
Disease occurs when an individual’s autoregulatory abilities
are compromised.We encounter this scenario when accumulated
stresses overpower the autoregulatory abilities, thereby
impinging tissue robustness. These persistent perturbations
can manifest as disease over time (Schadt, 2009; Furlong, 2013;
Baffy and Loscalzo, 2014; Vuillon and Lesieur, 2015). As humans,
we regularly encounter genetic, epigenetic, and environmental
perturbations apart from others that challenge the robustness
of our biological networks. This continuous challenge may
negatively impact autoregulatory ability, and lead to a “rewiring”
of these networks to new adaptation and compensation states.
Over time, these negative impacts may gradually progress to
eventually result in disease.
Participants also linked this conceptualization of disease
with biological networks, considering the consequences of this
interconnectivity for disease progression. These consequences
are evident in the case of an inflammatory response, where
chronic inflammation coincides with structural changes in a
tissue and in remodeling the microenvironment (Nathan, 2002;
Nathan and Ding, 2010). Given that many tissues and organs are
connected via networks of functional interdependencies, stresses
or perturbations that compromise autoregulatory abilities can
cause a ripple-like effect throughout networks of interconnected
tissues. This propagation facilitates disease progression by
proliferating distorted information flow.
The concept of modularity is used to propose how
pathophysiological events tend to organize and the impact of this
organization on health maintenance. Modules are self-organized
units of individual components that are grouped according to
a certain set of rules (e.g., a common function), and that allow
networks to optimize their dynamics and adapt to disturbances
(Newman, 2006; Loscalzo et al., 2007; Rollié et al., 2012).
Modularity helps networks to contain perturbations, support
autoregulation, and minimize the effects of disease on the system
(Kitano, 2004).
As many diseases are interconnected by shared
pathophysiological events, recent research has identified a
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common network that is perturbed in the majority of chronic
diseases. We call this network a “common disease-state
signature” (Suthram et al., 2010; Janjic´ and Pržulj, 2012). Many
diseases share common functional modules, suggesting that
treatment courses and medications may be more effective by
targeting these biological networks rather than the historically
more common approach of targeting single molecules. This
overlap across biological networks is a particularly advantageous
framework for understanding the aging process and age-related
diseases in novel ways. Multitarget drugs that target hubs,
bridges, or other areas of network overlap may therefore be
more effective and lead to fewer side effects than the more
common single-target, “magic bullet” drug design (Simkó et al.,
2009). From the perspective of BrSM, optimal therapeutic access
points may be discovered by utilizing these pathological threads
between seemingly unrelated diseases. This pathophysiological
connectivity may be a pathway to supporting a future of a
network pharmacology (Erler and Linding, 2010; Barabási et al.,
2011; Li et al., 2011), where networks themselves are the focus of
medication design and therapies.
Experts also acknowledged that sustained perturbation in
information flow (e.g., blocks to autoregulation) precipitates
the inability of regulatory networks to maintain functionality.
Indeed, the transmission of biological information maintains
a cardinal role in supporting and regulating the dynamic
equilibrium found in robust networks.
What is the nature of biological information most
relevant to BrSM? Participants viewed information theory
and thermodynamics as fundamental for understanding the
medicinal relevance of a biological system. Beyond these areas
that are already well integrated into systems biology, participants
considered two broad categories of biological information
as supporting system robustness. The first category includes
sequence information that is responsible for encoding molecular
machineries. This type of information is often referred to as the
“parts list” of sequence information that reductionist medicine
techniques have decoded.
Additionally, regulatory network information is thought to
be responsible for orchestrating the particular behaviors of
molecular machineries, and is thought to be transmitted by non-
coding RNA across levels of biological structures (molecules
to cells, cells to tissues, etc.). A theory of genomic dark
matter also surfaced on the concept map, positing that a cell’s
dynamic response to inputs from the microenvironment is
governed by non-coding, RNA-regulated molecular machineries
(St. Laurent et al., 2012). Participants believed that these
molecular machineries support the notion that a cell’s interaction
with its immediate environment is in fact a coherent pattern, and
is not a disordered or otherwise chaotic flow ofmolecules as some
might assume. This coherence is thought to be sustained in part
by a computational matrix that directs action within and across
molecular networks, and exists as a result of low affinity RNA
and protein interactions. Recent research lends further support to
the role of non-coding RNAs in health and disease. For example,
non-coding RNAsmaymediate stress response pathways of some
diseases such as Alzheimer’s (St. Laurent et al., 2009), and are
secreted by immune cells, stem cells, adipocytes, and blood cells
(Chen et al., 2012). From a diagnostic perspective, the presence of
non-coding RNAs in serum and other bodily fluids may suggest
their potential as clinical biomarkers (Iorio and Croce, 2012).
Both macro and micro scales of information regulation hold
prominent places in this model. At the most expansive level,
the interconnectivity of molecular networks creates a global
biochemical network containing numerous function-specific
networks and feedback loops. In BrSM, health-disease status is
governed by the particular integration of these networks as the
global autoregulatory network, and the orchestration of their
responsiveness to environmental stimuli.
Whereas systems level information regulation is a critical
concept, participants also considered the cellular scale of
information regulation. The role of the microenvironment as a
critical supporter of healthy cells (Buttle, 2007) and as a conduit
of biological information in tissues (Nathan and Ding, 2010)
was regarded as fundamental. A healthy microenvironment
encompasses the biochemical and biophysical signals that a cell
receives from the extracellular matrix, neighboring cells, and
the immune system, and is necessary for a cell and tissue to
maintain their function and autoregulatory ability (cell turnover)
(Pellettieri and Sánchez Alvarado, 2007; Duarte et al., 2015;
Fu et al., 2015; Mesa et al., 2015). Regulation at this more
micro level takes place within the tissue via the extracellular
matrix, intracellular cytoskeleton, and nuclear matrix, all of
which are interconnected by commonly utilized molecules. The
extracellular matrix can be considered an “information highway,”
where biochemical, physical, and neural signals are processed
and subsequently affect network robustness. In addition to
robustness, signaling within the microenvironment supports
other processes such as immunological synapse formation in
the immune system (Springer and Dustin, 2012; Dustin, 2014),
and others related to inflammation (Loscalzo et al., 2007;
Dustin, 2012). We explore the role of the extracellular matrix
in inflammatory processes in more depth in the subsequent
section.
Inflammation as a Central Regulatory
Mechanism for Maintaining Tissue Homeostasis
From a pathophysiological perspective, inflammation is a
common feature of many disorders and is strongly associated
with chronic and age-related diseases that continue to escalate in
incidence under the current healthcare model. Inflammation is
traditionally viewed as something to be reduced or suppressed
(Widgerow, 2012; Women’s International Pharmacy, 2012).
BrSM puts forth a far more comprehensive and dynamic view of
inflammation, beyond simply a static symptom that needs to be
eliminated. In fact, BrSM embraces physiological inflammation
as an extension of the autoregulatory capacity of the body,
capable of restoring a healthy tissue’s functional state (Sansonetti,
2011; Chovatiya and Medzhitov, 2014; Kotas and Medzhitov,
2015; Serhan et al., 2015). The model aids us in more precisely
distinguishing among adequate, resolving, and excessive or
insufficient inflammatory responses, and in guiding clinicians
toward recognizing inflammation as a potential tool in patient
treatment selection and a vital part of homeostasis, rather than as
the ubiquitous enemy.
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Inflammatory mechanisms are switched on by various
exogenous and endogenous stressors that aim to eliminate initial
stressors and adjust to a changed environment by establishing
new homeostatic set-points (Miyake and Kaisho, 2014; Kotas
and Medzhitov, 2015). Inflammation can be considered a central
physiological mechanism that supports the body’s ability to
resolve dysfunctional states in order to regain tissue functionality,
and in a way that tissues cannot accomplish themselves.
Inflammatory processes can therefore play a cardinal role in both
disease progression and regression.
Non-resolving, chronic inflammation coincides with its
common pathological clinical association, manifesting in chronic
diseases such as atherosclerosis, cancer, asthma, diabetes,
rheumatoid arthritis, and others (Nathan and Ding, 2010;
Hellmann et al., 2012; Young et al., 2014; Fredman et al., 2015).
In understanding the inflammatory mechanisms that lead to
these pathologies, BrSM also recognizes the intersection between
inflammation and information regulation concepts discussed in
the prior sections. We find concepts such as balance and systemic
effects as extending into this region of the model, reinforcing the
notion of biological interconnectivity as an undercurrent of the
model as a whole.
Whereas pro-inflammatory mechanisms, anti-inflammatory,
and pro-resolution pathways are all involved concurrently to
regulate the duration and severity of an inflammatory response,
a persistent imbalance of these mediators can lead to pathology
and chronicity (Ariel et al., 2006; Beck et al., 2009; Nathan and
Ding, 2010; Valledor et al., 2010; Kotas and Medzhitov, 2015;
Serhan et al., 2015). For example, inflammatory mechanisms
can influence the production of damage-associated molecular
patterns (DAMPs), resulting in positive feedback loops in which
the inflammatory response itself provides a persistent stimulus
for macrophage and lymphocyte recruitment (Foell et al., 2007).
This cyclical, excessive production drives host damage and
chronic inflammation.
Not all cases of tissue stress or malfunction result in
acute inflammatory responses. Insufficient but persistent stimuli
can also provoke low grade inflammatory responses. This
so called para-inflammation is maintained at a low level
without resolution, and can lead to tissue damage and chronic
inflammation (Chovatiya and Medzhitov, 2014; Netzer et al.,
2015). The model emphasizes that the inflammatory process
itself is not dangerous, as it can be resolved by endogenous
molecules and mechanisms; rather, it is the non-resolving,
chronic or overwhelming acute inflammatory response that leads
to pathology. Whereas acute inflammation is typically seen as a
target for prevention, BrSM uses this kind of evidence to support
the notion of acute inflammation as a homeostatic mechanism
that may be supported in a controlled manner to stimulate
resolution. To this end, clinicians may find that improving a
patient’s self-regulatory abilities is a pathway toward attaining
resolution initiation naturally. Nonetheless, caution should be
taken in overgeneralizing this phenomenon, which may not
present itself in other tissues or organs such as the brain, for
example.
We underscore participants’ recognition that the current
healthcare model has historically paid little attention to the
inherent connectivity between local and system levels of
physiological responses such as inflammation. In BrSM, this
connectivity across levels of biological organization is nothing
short of essential in understanding disease and improving
treatment.
Beyond these pathological distinctions, participants
understood inflammation as practically relevant to treatment
in two main ways. The inflammatory system is considered the
target for stimulating or optimizing disease resolution. The
bidirectional communication using inflammatory pathways
between a cell and its microenvironment, functions as a
homeostatic control mechanism for many tissues. Complete
inflammation resolution requires not only the removal of
immune cells, but also the normalization of chemokine
gradients and the withdrawal of survival signals. Disordered
fibroblast behavior, for example, can contribute to chronic non-
resolving inflammation by sustaining inappropriate retention
of leukocytes within inflamed tissue (Buckley et al., 2001;
Buckley, 2011). It therefore seems only reasonable to target the
tissue microenvironment in parallel with the stressor and the
infiltrating immune cells when treating chronic inflammation
(Serhan et al., 2007; Valledor et al., 2010).
With regard to treatment, it is possible that with the
ability to mimic or inhibit extracellular matrix functions,
we could provide a novel means to influence and resolve
chronic inflammation and reveal promising therapeutic targets.
Another potential option in treating chronic inflammatory
disease might be to permit the restoration of autoregulatory
processes in the extracellular matrix, including physiological
inflammation, by removing any toxins, stresses, deficiencies, or
other perturbations that are interfering with its structure and
function. Potentially, this option might also be applicable to
cancerous microenvironments. The link between inflammation
and tumor development is well established (Sommer, 2014;
Blaylock, 2015). Targeting autoregulatory mechanisms that aim
to restore original immunosurveillance and neuroendocrine
regulation as part of the comprehensive treatment protocol might
increase responsiveness of the patient. For an excellent discussion
of evolving approaches to cancer management, see McGranahan
and Swanton (2015).
In addition to thinking about the microenvironment as
a context for intervention, participants hypothesized about
how patterns of inflammation and their effects on the
microenvironment can be used to assess the state of a patient’s
autoregulatory network. Because the status of the autoregulatory
network is a major player in resolution, it is logical to seek ways of
incorporating it into diagnosis. Inflammatory patterns and their
effects on the microenvironment may prove a gateway to this
type of assessment. We discuss how participants considered this
concept as we move to focus specifically on activating the model’s
scientific principles in the hands of the clinician.
Incorporating the Health-disease Continuum into
Patient Diagnosis
BrSM encapsulates a health-disease continuum, along which
a patient can be diagnosed in accordance with phases of
disease progression, treated via multiple therapeutic access
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points, and monitored based on how networks manifesting
pathophysiological processes resolve to a state of health. Disease
progression is the outcome of both the inflammatory response
to network perturbation and the effect of this response on
the microenvironment. Patient history, physical examination,
and laboratory tests are among the sources of information that
clinicians can use to determine an individual patient’s state along
this continuum.We anticipate that as genomic profiling becomes
part of routine testing, this data will allow us to be even more
specific about where a patient stands along a scale of health and
disease, and will also provide us with information on the status of
the autoregulatory network (Figure 3).
A goal of BrSM is to eventually develop biomarkers that
predict the health-disease continuum, and that match therapeutic
interventions to the specific stage of a patient’s disease. Whereas
historically we have thought about disease in a relatively linear,
gene-centric, and deterministic way, we now realize that this
perspective is too limiting and is unable to explain either the
dramatic rise in the rates of these diseases over the past 50
years or the relatively minimal penetrance of gene mutations
in most chronic diseases (Renz et al., 2011). The modern view
realizes that extrinsic factors such as nutrition, the microbiome,
and the environment, combined with intrinsic factors such as
the gut and respiratory mucosa, must be collectively considered
as affecting gene expression, possibly via the processes of
epigenetics. The complexity of these chronic conditions demands
that scientists and clinicians also be complex thinkers, studying
the interaction of these factors in a dynamic temporal and spatial
way, and defining and describing diseases on the basis of their
intrinsic biology in addition to traditional signs and symptoms
(National Research Council, 2011). One solution would be
rethinking the way of classifying diseases, adding new elements
possessing certain predictive value that would allow the clinician
to dynamically monitor patient condition and adjust treatments
in a timely manner. From that perspective, the BrSM model
proposes incorporating autoregulatory capacity assessment as
part of the diagnosis, providing additional information to further
individualize the treatment plan.
Creating a More Effective Clinical Toolbox by
Choosing the Right Therapeutic Strategy, Clinical
Focus, and Bioregulatory Intervention
As we explore the remaining areas of the model, concepts such as
the inflammatory and microenvironment responses to network
perturbation, disease progression, and autoregulation serve as
key insights for more fully realizing how BrSM may actually
propagate changes in medical treatment. In this section, we
discuss how the strategic implementation of BrSM approaches
the patient condition in ways that are distinct from the current
healthcare approach.
When presented with a case, a clinician using the BrSM
approach will initially assess whether the patient exhibits an
inflammatory response to network perturbation at the systems
level. Inflammatory responses can vary in manifestation from
mild to moderate acute, severe acute, acute with transition to
chronic, and chronic. The actual nature of an inflammatory
response can also vary by condition, including network
perturbation with resolution as in the case of pneumonia,
early remodeling as in the case of asthma, degeneration and
fibrosis as in the case of COPD, or proliferation as in the case
of lung cancer. The extent of an individual’s dysregulation at
both the local and systems levels guides clinicians as to which
interventions to undertake. In some cases, a patient’s state may
dictate the immediate use of suppressive or replacement therapy,
complemented (or not) with bioregulatory therapy. In other cases
the bioregulatory therapy might be the primary or even the only
treatment approach.
These clinical insights can be used to determine the degree
of disease progression and, in turn, the appropriate clinical
focus, therapeutic strategy, and medications with bioregulatory
properties required to promote effective resolution (Figure 4).
Depending on the condition and health history that a patient
presents, the clinical focus and appropriate treatment will
be individualized accordingly. Clinical focus may include
the inflammatory network exclusively, the inflammatory and
remodeling networks simultaneously, or also the metabolic
network, blood sugar levels, or other physiological processes as
well, depending on the patient. Likewise, appropriate treatment
may include one or two medications with bioregulatory
properties, or the use of bioregulatory treatment as an adjuvant
to a patient’s current treatment program. To date, this graded
treatment approach is achieved through empirical assessment of
the concepts in the clusters related to dysregulation (Figure 2).
In the future, predictive biomarkers and diagnostics developed
in the “omics” realm will provide a more in-depth, validated
approach to assess the individual’s autoregulatory capability
in the presence of a stressor. Capturing dynamic changes
would require multiple assessments during the treatment period.
Therefore, an easily applied and inexpensive tool is desired. PCR-
based biomarker panels can be purchased for as low as $20–40 per
sample (Sahasrabudhe et al., 2014). This type of tool could take
the form of a diagnostic index based on specific objective routine
parameters, like FIB-4 or NIKEI in non-alcoholic fatty liver
disease (Demir et al., 2013), or prognostically relevant clinical
judgment questions (Ganna and Ingelsson, 2015), or as a blood-
sample based biomarker panel (Mesko et al., 2010; Etheridge
et al., 2011; Hu et al., 2014), or as a combination of all mentioned
options. With next-generation sequencing costs falling rapidly,
some solutions are already being tested for use in the clinical
laboratory (Onsongo et al., 2014). Some studies indicate that
next-generation sequencing solutions may become cost effective
(Gallego et al., 2015; Li et al., 2015). Other recent evidence
suggests that whole-genome transcriptomics captured at certain
time periods before and during treatment could reflect the
dynamics of transcriptome changes in response to perturbations
and interventions (St. Laurent et al., 2013). Arguably, this would
also allow for identification of any persistent perturbations that
reflect dysfunctional autoregulatory cues. These trends indicate
that potentially cost-effective biomarker-based tools are not
outside of our reach. The two major challenges to BrSM are to
reduce the costs of repeated diagnostic testing, and to identify
effective responses for persistent perturbations.
Medication is an undeniably important part of the current
healthcare approach and modern medicine more broadly. BrSM
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FIGURE 4 | Novel conceptualization of disease progression using
patient autoregulatory status. Disease progression is commonly
understood as the worsening of a disease over time. In 1980, the World
Health Organization published the International Classification of
Impairments, Disabilities and Handicaps (ICIDH) with the objective of
providing a widely accepted structure of the consequences of disease
and the implications for the lives of patients. Expanding on this model,
this figure presents a conceptualization of patient autoregulatory status.
(A) The concept of disease progression, adapted from the 1980 WHO
ICIDH model. Blue-to-black lines indicate stages in which a given disease
is progressing, and ♦ depicts principal milestones between stages. The
dashed line indicates that there is no strict sequential order between
stages or milestones. A linear structure is used for simplicity. (B) A
schematic conceptualization of disease progression as a four-quadrant
map (using the BrSM model as a framework, disease progression is
considered as the Patient’s Health-Disease Continuum). The arrowed
dashed lines represent the hypothetical disease progression of patients X
and Y. In contrast to a more simplified, linear approach of identifying
disease stages in clinical decision-making, this map positions stages in
relation to dysregulation parameters represented by the horizontal and
vertical axes. Within the context of the BrSM model, systemic
dysregulation parameters are conceptualized as Inflammatory Network
Response to Perturbation and local dysregulation parameters as
Microenvironment Response to Inflammation. The farther along either axis
a patient’s disease progression is positioned, the greater the
dysregulation. It is postulated that the ratio between these two
dysregulation parameters theoretically defines the autoregulatory status of
a patient. Mapping individual’s autoregulatory status in a temporal fashion
will produce a visualization of individualized disease progression. It is also
postulated that a certain area of the map displays robust autoregulation
capacity (marked area) in contrast to other areas where autoregulatory
capacity is reduced. The therapeutic strategy proposed by the BrSM
model proposes that a therapeutic effort is focused on “moving” a
patient’s autoregulatory status (represented by the green dashed arrows)
to a state of more favorable autoregulation capacity. It is in this more
favorable state where bioregulatory therapy can be most efficiently applied
to strengthen autoregulation (hypothetical Patient X). It is assumed that in
more advanced cases, it may not be possible to reach a state of
favorable autoregulation capacity (hypothetical Patient Y). Bioregulatory
intervention would be based on the patient’s position on the map and,
depending on the individual case, could serve as a primary, secondary, or
complementary treatment to the suppressive or replacement therapy.
proposes an alternative conceptualization of medication—its
design, how it is used—using lessons from the relevant scientific
elements discussed prior. One objective of this conceptualization
speaks specifically to the mounting evidence of side effects
and other unintended consequences of many widely used
medications developed under the current reductionist healthcare
model. The reductionist or reactionary approach often uses
medication under the guise of a “magic bullet” that can eliminate
a disease cause or symptom. This single-target perspective
tends to neglect consideration for how these medications
unintentionally impact the overall regulatory ability of the human
organism.
Consequently, model participants noted the potential for
BrSM to include a novel approach to medication, rooted in
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the scientific principles that support the paradigm as a whole.
Medications should be designed to mimic, modulate, or promote
the body’s natural resolution mechanisms instead of interfering
with them. Of course, the precise design and application of such
medications will depend on the specific context of a patient’s
condition, as described above. Nonetheless, the overall goal
remains: Increase the ability to alter disease progression by
promoting or mimicking resolution processes while incurring
minimal side effects (Perretti and Dalli, 2009; Serhan, 2011;
Rogerio et al., 2012). These concepts lead us to a key component
of BrSM’s therapeutic strategy: Interventions should utilize
multitarget medications that act in concordance with multiple
network interactions, feedback loops, and biorhythms inherent
in autoregulatory networks. In other words, the efficacy of a
medication in reversing the clinical picture of disease may be
determined by its capacity to influence multiple interactions.
As model participants endorsed, when multiple independent
targets of the same pathways are inhibited simultaneously, a mild
inhibition of each target can achieve a much larger therapeutic
window and therapeutically relevant effect than single-target
treatments (Csermely et al., 2005).
One important question is precisely how these medications
can be derived. The notion of combination chemistry and
synergy are viable strategies. Whereas the concept of synergy
has been used for some time in various scientific disciplines,
its use in medication design offers a novel application, and
may be one that allows for more comprehensive and broader
reaching effects. Combinatorial strategies may prove effective
by inhibiting the pathophysiological pathways implicated in
disease, while simultaneously altering other interconnected
pathways that also influence disease regression. By employing
a network pharmacology strategy, a medication can affect an
entire signaling process. This strategy can include active agents
that weakly target different proteins that are present in a given
signaling network.
Put simply, a multicomponent strategy, applied through
the lens of BrSM, has potential to influence a wide range of
information flows in disease-perturbed networks, allowing for
efficient control over such networks, and promising higher
drug safety and less drug resistance. These benefits aim to
trump the long-term effects of single component strategies,
from which various undesirable consequences result. For BrSM,
modest modulation, lower concentrations, and synergistic effects
collectively suggest a potentially powerful adjuvant to the current
medication model.
In sum, experts in this initiative clearly recognized an
important link between multi-combination medication
design and BrSM’s scientific basis, noting that multitargeting,
multicomponent medications can be used to purposefully
influence biological information of regulatory networks and
in turn impact reversal of disease. Perhaps the most beneficial
aspect of this medication approach is in the potential to target
multiple nodes of the autoregulatory networks involved in
disease. This influence may not be limited to a particular target
tissue or organ. As many disease-perturbed networks are present
in many tissues, these medications may be able to address
distorted information flow throughout a patient.
By addressing these underlying dysregulations through
optimization of the autoregulatory system, the bioregulatory
approach is potentially drug sparing and may lead to diminished
incidence of iatrogenesis, patient morbidity, and patient
mortality. We emphasize that above all, this approach is
presented as a supplementary pharmacologic treatment that
may lead to improved patient outcomes alongside other non-
pharmacologic approaches. Although medicine holds important
potential in changing health outcomes, we do not diminish the
profound impact of other lifestyle behaviors such as diet and
weight management that have proven to have a remarkable
impact on chronic disease prevention (Ford et al., 2009).
Discussion
At the most expansive level, participants summarized two
primary undercurrents of BrSM: information regulation and
disease resolution. We find these themes permeating all regions
of the model, perhaps unsurprisingly given that the approach is
purposed to bridge systems biology with a clinical application.
Indeed, BrSM is advantageous in its proactive approach to disease
management, supporting the temporal evolution of patient
condition. In this regard, BrSM adds dynamic features to a
historically static perspective of patient condition. This approach
embraces change, both in terms of activity at micro and macro
network levels, as well as in how disease resolution is achieved
through endogenous and exogenous means.
The inflammatory response to network perturbation can be
used to assess how well the autoregulation of physiological
inflammation is able to induce homeostasis. The ability to
observe non-resolution of acute physiological inflammation and
a movement toward overwhelming acute inflammation (as seen
in multi-trauma cases, for instance) or chronic inflammation,
strongly suggests a breakdown in network information flow.
The microenvironment response to inflammation is another
potential surrogate for assessing regulation capacity. As we
can observe changes in the remodeling pattern of the
microenvironment as a disease becomes increasingly chronic, it
seems prudent to consider such remodeling as a natural indicator
of disease progression. In accordance with this hypothesis, it
is not surprising that markers of inflammation and matrix
turnover are increasingly cited as predictive biomarkers of
disease progression, e.g., in chronic stress (Hänsel et al.,
2010), chronic prostatitis (Penna et al., 2007), atherosclerosis
(Libby, 2002), chronic obstructive pulmonary disease (Vestbo
et al., 2008), ankylosing spondylitis (Visvanathan et al., 2008),
and non-alcoholic fatty liver disease (Wieckowska et al.,
2006). Moreover, a novel inflammatory biomarker, YKL-40, is
proposed as the clinically relevant alternative to CRP (Johansen,
2006).
Further research with “omics” platforms, especially genomics,
will likely validate, refine, or even replace the use of these
surrogates in clinical decision-making. These platforms are
especially well-suited for a systems medicine approach, as they
embrace the analytic complexity of biological networks, and are
therefore also likely to assist in identifying the various targets of
a multicomponent medication design.
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Areas for Future Research
Like many recent advances in medical theory development,
BrSM faces various challenges in actualizing its clinical potential.
Participants acknowledged that much ongoing research is needed
to validate and expand its scientific and clinical evidence base. In
this section, we summarize the major areas for future research
concentration that will support the practical application of the
BrSM approach. Our hope is that this paper encourages scientific
and clinical communities to explore these areas in their own
work, and consequently help to propagate the growing need for
more effective therapeutic strategies.
The ability to measure the multiple networks involved in
disease processes is a critical step in addressing disease at the
systems level and understanding the global autoregulatory
network. Whole genome transcriptome analysis provides
an optimal analytic tool for understanding the genomic
quantification of disease evolution and health-disease status.
High resolution transcriptome maps of disease will allow
for the identification of therapeutic targets and will further
guide diagnosis and medication design, thereby enhancing the
practical value of the BrSMmodel. The advent of next-generation
sequencing methods will also allow for a more individualized
picture of health and disease, further advancing personalized
medicine (Sripada et al., 2012).
Research on the microenvironment or “terrain” in which
inflammation takes place will provide more comprehensive
insight into treating the underlying causes of chronic
inflammatory conditions, extending the therapeutic value
of any medical intervention beyond targeting symptoms alone.
Chronic inflammation, however, is biologically complex;
therefore, the same intervention could produce different effects
in different patients at different times (Nathan and Ding, 2010).
Future therapeutic systems would benefit from the ability to
assess the current inflammatory profile of individual patients,
which could then help to identify and locate any blocks to
resolution, as well as underlying pathologies.
Furthermore, the ability to measure the history and
culmination of an individual’s resolution factors over
time can allow the clinician to better evaluate the overall
inflammatory status of a patient and prescribe the most
appropriate treatment.
It is important to note that the inflammatory network is
not the only perturbed system of a particular disease, or even
the main target of the therapeutic approach. The endocrine,
neurological, and other systems are affected as well. We posit that
the clinical picture of inflammation may nonetheless be used as
a surrogate marker to classify known diseases in order to predict
the status of the autoregulatory network.
Development of a formal diagnostic platform for BrSM is
likely to aid in realizing and validating the relationships among
its scientific and clinical elements. Diagnostics are also essential
in making therapeutic decisions. The ability to evaluate the
autoregulatory patterns of a patient is critical in determining the
appropriate combination of treatments to achieve homeostasis.
Although empirical inflammatory patterns or allostatic state
models may provide useful surrogates for measurement in the
absence of formal diagnostics (Romero et al., 2009; Oken et al.,
2014), genomic and other “omics” patterns are likely to better
delineate the autoregulatory status of a patient. The information
elicited from genomic patterns can potentially address the need
to better understand the scientific basis that relates the more
conceptually sound anchors of the model.
Appropriate diagnostic technological platforms are also
essential for capturing relevant biological information at the
necessary level of detail. In the context of BrSM, lipidomics,
metabolomics, genomics, and proteomics are technologies that
can help to detect and monitor the autoregulatory state of
a patient in order to diagnose more comprehensively. New
technologies will also allow for numerous markers to be tested
simultaneously, expanding the diagnostic utility of already
commonly tested clinical fluids such as blood (Hood and Flores,
2012), saliva (Zauber et al., 2012), and urine (Sharma et al., 2011).
In the near term, “omics” technologies are relatively expensive
because they are still evolving and are quantifying the entire
genome, transcriptome, or proteome. In 3–5 years, as these
technologies become more price competitive and the relevant
genes, transcripts, and proteins become well known, focused
“omics” tests will be fast and inexpensive methods for guiding
BrSM therapy.
Multitargeting medications suggest a promising pathway for
influencing biological information of regulatory networks, and
with a greater degree of agency and purpose than current
widely used medications (Csermely et al., 2005). Given the
current healthcare and medical challenges, it is evident that the
single-molecule, single-target paradigm does not provide the
specificity and sophistication that a multitargeting model has
potential to offer. To this end, new medications and treatment
protocols are warranted to target and bioregulate perturbed
autoregulatory networks toward resolution. In addition to new
medication design, this strategy can be applied to the vast dataset
(Comprehensive Medicinal Chemistry2) of existing drugs to
create new, unique formulas. This approach is already used for
cancer therapeutics, which currently include eight drugs that
inhibit more than one regulatory enzyme. Evidence shows that
thismultiple target activity is advantageous in an oncology setting
(Knight et al., 2010).
A multitargeting medication strategy inevitably raises
questions about the number of known molecular targets that
can be used for future combination design. Whereas current
databases include targets derived from biological information
sequencing, there is little evidence of bioregulatory network
information. Future database development that considers the
complexity of regulatory information will likely expand the drug
target landscape to unprecedented levels. Nonetheless, existing
knowledge can support the design of medications that will act on
multiple targets across known disease networks.
At this point, three drug design strategies can be
suggested. First, multiple individual medications can be
used simultaneously. This strategy is most in line with current
medical approaches, as in the case of treatment protocols for
HIV, tuberculosis, primary hypertension, osteoarthritis, lupus
2Comprehensive Medicinal Chemistry (CMC). Available online at: http://accelrys.
com/products/databases/bioactivity/comprehensive-medicinal-chemistry.html
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erythematosus, metabolic syndrome, fibromyalgia, and others.
Second, multicomponent medications can be developed that
contain two or more active ingredients (e.g., Combivir, Atripla,
Advair, Caduet, Iberogast, Traumeel). Third, single-component
medications can be developed that act on multiple targets
simultaneously. This is the major objective of chemogenomics, a
novel pharmacology field (Medina-Franco et al., 2013; Sakharkar
et al., 2015). BrSM embraces all three strategies, to the extent that
they support the intent of neither blocking nor interfering with
endogenous resolution pathways that help to reduce therapy side
effects and promote long-term benefits.
Finally, the potential to influence stem-cell niches through
medication begs the question as to whether using niches as drug-
targets may be a valuable treatment component. Stem cells exist
in niches which act as basic physiological units that integrate
signals in order to mediate stem cell response to organism needs.
Niches essentially regulate the extent to which stem cells are
involved in tissue repair, generation, and maintenance. While
niche manipulation has been broadly considered in the context
of various chronic conditions (e.g., cardiac repair, diabetes,
cancer) (Department of Health andHuman Services, 2006), these
concepts may also apply to regulation and mediation of chronic
inflammatory conditions. By targeting the inflammatory system
in treatment, stem cell niches may be influenced and in turn
impact the regeneration of affected tissue.
Future clinical research may consider whether
bioaccumulation of toxins in tissues can negatively influence
cellular health, as environmental toxins and metabolic waste
products can accumulate in the extracellular matrix and
cause disease. Recent research in various health disciplines
demonstrates that deficiency and toxicity are common
etiological determinants of contemporary ill-health (Genuis,
2012). Bioaccumulation of pesticides in adipose tissue, for
example, increases the total body burden of intoxication and
may lead to neural, immune, and endocrine toxicity (Crinnion,
2000). This line of research also suggests a relationship between
bioaccumulation of environmental toxins and perturbations in
the immune response/inflammatory network that should be
explored further in the context of BrSM.
The ability to identify molecular networks shared by
the progression of multiple diseases suggests that modeling
an individual’s health-disease continuum would also provide
clinically relevant information. In one study, whole-genome
sequencing was applied to a blood sample from a patient with
a history of vascular disease and early sudden death as a
means of developing a model of the patient’s individual disease
network. The resultant model displayed an interconnected
picture of disease modifiable factors such as smoking, diet,
alcohol, exercise, and medication use, as well as risks for
developing coronary artery disease, obesity, osteoarthritis, and
Type 2 diabetes. Given the high correlation among these
diseases, the authors concluded that information regarding
individual patient disease risk and response to drugs can in
fact be derived from whole-genome sequence data (Ashley
et al., 2010). In another example, researchers identified a set of
molecular networks that are perturbed during the progression
of a prion disease in mouse models. The researchers monitored
the global molecular information from onset, to the appearance
of symptoms, to the final disease stages. Interestingly, the four
identified networks of the prion disease are also those perturbed
in other neurodegenerative diseases such as Alzheimer’s disease,
Huntington’s disease, Parkinson’s disease, and amyotrophic
lateral sclerosis. This line of research further supports the
potential insight derived from understanding and identifying
molecular networks that are shared by the progression ofmultiple
diseases, and applying this insight to modeling an individual’s
disease evolution (Hwang et al., 2009).
From a clinical practice perspective, this research suggests that
in any individual patient, disease interconnectedness (by shared
molecular events) represents the individual’s disease evolution,
reflected in the patient’s medical history. The results support
the development of personalized medicine, and provide an
opportunity for the disease evolution concept to be formally
introduced and studied in the clinical setting. Some research
groups within the scientific medical community have already
begun developing disease models, such as in the case of diabetes,
and have validated these models in an RCT setting (Eddy and
Schlessinger, 2003). The success of this modeling supports future
research that looks at simulating the dynamic evolution of
health-to-disease processes in a way that can be used to predict
the response of a whole inflammatory/wound-healing biological
network, rather than the response of particular inflammatory
mediators.
Conclusion
Although various challenges remain in bringing BrSM to
patients, the foundation outlined in this model offers fruitful
grounds for next steps. Looking ahead, the BrSM scientific
community should pursue focused research projects that aim to
establish the molecular fingerprint of autoregulatory networks,
map the health-disease continuum, improve autoregulatory
capacity diagnostics from empirical to objective assessment tools,
and test various bioregulatory treatment strategies in clinical
settings. Pharmacoeconomic studies evaluating cost-effectiveness
of BrSM diagnostics and therapies will become an important
part of this research. Ongoing research in the fields of systems
biology also promises to strengthen the scientific landscape of the
BrSM approach. Empirical evidence from clinical experience and
the development of patient registries will continue to validate its
ability to resolve chronic conditions.
The interconnectivity that sustains the human organism is
undeniable.We anticipate that approaches like BrSM can provide
roadmaps for connecting the dots between scientific discoveries
and ideal clinical outcomes. While we are still in the early stages
of this paradigm shift, emerging conceptual models such as that
presented in this paper promise to pave the way for a future of
medicine that is cost effective, patient-centered, and better able
to achieve improved medical results.
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